Centessa Pharmaceuticals plc
CNTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $15,000 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $15,000 | $0 |
| % Margin | – | – | 100% | – |
| R&D Expenses | $41,563 | $42,741 | $33,443 | $60,874 |
| G&A Expenses | $12,227 | $11,912 | $12,334 | $13,706 |
| SG&A Expenses | $12,227 | $11,912 | $12,334 | $13,706 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $53,790 | $54,653 | $45,777 | $74,580 |
| Operating Income | -$53,790 | -$54,653 | -$30,777 | -$74,580 |
| % Margin | – | – | -205.2% | – |
| Other Income/Exp. Net | -$935 | $5,088 | $6,039 | -$35,699 |
| Pre-Tax Income | -$54,725 | -$49,565 | -$24,738 | -$110,279 |
| Tax Expense | $166 | $778 | $1,397 | $1,050 |
| Net Income | -$54,891 | -$50,343 | -$26,135 | -$111,329 |
| % Margin | – | – | -174.2% | – |
| EPS | -0.41 | -0.38 | -0.2 | -0.84 |
| % Growth | -7.9% | -90% | 76.2% | – |
| EPS Diluted | -0.41 | -0.38 | -0.2 | -0.84 |
| Weighted Avg Shares Out | 134,163 | 133,677 | 133,034 | 132,050 |
| Weighted Avg Shares Out Dil | 134,163 | 133,677 | 133,034 | 132,050 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,765 | $4,380 | $7,890 | $4,845 |
| Interest Expense | $2,890 | $2,884 | $2,877 | $2,479 |
| Depreciation & Amortization | $237 | $226 | $217 | $230 |
| EBITDA | -$51,598 | -$46,455 | -$21,644 | -$107,570 |
| % Margin | – | – | -144.3% | – |